All Online

1 - 2 of 2 results

Refine

Active filters

Lipid Disorders (Dyslipidemia)

Inhibitors of the PCSK9 protein represent an important new therapeutic class for patients with familiar hypercholesterolemia or established CVD who require further LDL-C lowering beyond what statins can provide. This Case Curriculum illustrates two patient scenarios for the use of PCSK9 inhibitors, and reviews selection of patients who require more intensive LDL-C lowering and clinical efficacy and safety data for these novel agents.


0.78 CME CREDIT

This session will review a number of clinically relevant trials/topics recently presented at the American College of Cardiology Scientific Sessions in March 2017, including updates in the management of patients with hypercholesterolemia, heart failure, valvular heart disease, arrhythmias, and more.